NeoGenomics (NEO) News Today $14.00 +0.41 (+3.02%) (As of 11/1/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period NeoGenomics (NEO) to Release Earnings on TuesdayNeoGenomics (NASDAQ:NEO) will be releasing earnings before the market opens on Tuesday, November 5, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=635831)October 29, 2024 | marketbeat.comNeoGenomics gains conditional approval for solid tumour assays in New YorkOctober 23, 2024 | msn.comNeoGenomics Receives New York State Approval for Neo Comprehensive™ Solid Tumor TestOctober 22, 2024 | finance.yahoo.comNeoGenomics (NASDAQ:NEO) Shares Down 2.5% - Here's WhyNeoGenomics (NASDAQ:NEO) Trading Down 2.5% - Time to Sell?October 16, 2024 | marketbeat.comRenaissance Technologies LLC Cuts Holdings in NeoGenomics, Inc. (NASDAQ:NEO)Renaissance Technologies LLC cut its holdings in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 89.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,300 shares of the medOctober 13, 2024 | marketbeat.comNeoGenomics Unveils AML ExpressOctober 8, 2024 | baystreet.caNeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid LeukemiaOctober 8, 2024 | finance.yahoo.comSei Investments Co. Has $3.66 Million Position in NeoGenomics, Inc. (NASDAQ:NEO)Sei Investments Co. raised its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 152.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 263,761 shares of the medical research company'sOctober 3, 2024 | marketbeat.comNeoGenomics Inc (NEO) Shares Up 3.95% on Oct 2October 2, 2024 | gurufocus.comPoint72 Asset Management L.P. Has $14.31 Million Stock Position in NeoGenomics, Inc. (NASDAQ:NEO)Point72 Asset Management L.P. lessened its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 53.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,031,608 shares of the medicalOctober 1, 2024 | marketbeat.comDimensional Fund Advisors LP Has $46.11 Million Stake in NeoGenomics, Inc. (NASDAQ:NEO)Dimensional Fund Advisors LP lifted its position in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 7.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,324,624 shares of the medical research compaSeptember 30, 2024 | marketbeat.comBrokers Offer Predictions for NeoGenomics, Inc.'s FY2024 Earnings (NASDAQ:NEO)NeoGenomics, Inc. (NASDAQ:NEO - Free Report) - William Blair boosted their FY2024 earnings per share (EPS) estimates for NeoGenomics in a note issued to investors on Tuesday, September 24th. William Blair analyst A. Brackmann now forecasts that the medical research company will post earnings of (September 27, 2024 | marketbeat.comQ4 2025 EPS Estimates for NeoGenomics, Inc. Cut by William Blair (NASDAQ:NEO)NeoGenomics, Inc. (NASDAQ:NEO - Free Report) - Equities research analysts at William Blair lowered their Q4 2025 earnings per share (EPS) estimates for shares of NeoGenomics in a research note issued to investors on Tuesday, September 24th. William Blair analyst A. Brackmann now anticipates thatSeptember 26, 2024 | marketbeat.comFred Alger Management LLC Has $25.45 Million Stock Position in NeoGenomics, Inc. (NASDAQ:NEO)Fred Alger Management LLC lowered its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 21.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 1,834,912 shares of the medical research company's stock after selling 504,854 shares during theSeptember 26, 2024 | marketbeat.comWhy CEO of Bay Area 'liquid biopsy' cancer test maker is stepping downSeptember 25, 2024 | bizjournals.comFreenome Announces CEO TransitionSeptember 25, 2024 | finance.yahoo.comNeoGenomics Hold Rating Maintained Amidst Ongoing Legal Challenges and MRD Assay Development UncertaintySeptember 25, 2024 | markets.businessinsider.comNeoGenomics' (NEO) Buy Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $19.00 target price on shares of NeoGenomics in a report on Wednesday.September 25, 2024 | marketbeat.comExpert Ratings For NeoGenomicsSeptember 24, 2024 | benzinga.comNeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 LitigationSeptember 24, 2024 | finance.yahoo.comBenchmark Reaffirms Buy Rating for NeoGenomics (NASDAQ:NEO)Benchmark restated a "buy" rating and issued a $18.00 target price on shares of NeoGenomics in a research note on Tuesday.September 24, 2024 | marketbeat.comFirst Light Asset Management LLC Acquires 480,396 Shares of NeoGenomics, Inc. (NASDAQ:NEO)First Light Asset Management LLC lifted its holdings in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 14.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,782,561 sharesSeptember 24, 2024 | marketbeat.comNeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Blair William & Co. ILBlair William & Co. IL lessened its stake in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 13.5% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 409,182 shares of the medical research company's stock after selling 63,68September 22, 2024 | marketbeat.comNeoGenomics, Inc. (NASDAQ:NEO) Stock Position Boosted by American Century Companies Inc.American Century Companies Inc. boosted its position in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 5.4% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,261,756 shares of the medical research company's stock afteSeptember 17, 2024 | marketbeat.comNeoGenomics, Inc. (NASDAQ:NEO) Given Average Rating of "Moderate Buy" by AnalystsNeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten brokerages that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the companySeptember 16, 2024 | marketbeat.comNeoGenomics to Present New Data at ESMO 2024, Highlighting the Value of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized TreatmentSeptember 11, 2024 | finance.yahoo.comNeoGenomics (NASDAQ:NEO) Shares Down 3.2% NeoGenomics (NASDAQ:NEO) Stock Price Down 3.2%September 9, 2024 | marketbeat.comNeoGenomics, Inc. (NASDAQ:NEO) Shares Acquired by Candriam S.C.A.Candriam S.C.A. raised its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 29.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 487,026 shares of the medical research company's stockSeptember 9, 2024 | marketbeat.comEmerald Advisers LLC Cuts Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO)Emerald Advisers LLC lowered its stake in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 3.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,844,615 shares of the medical research company's stock after seSeptember 8, 2024 | marketbeat.comNeoGenomics to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 29, 2024 | businesswire.comNeoGenomics, Inc. (NASDAQ:NEO) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesShares of NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the compaAugust 22, 2024 | marketbeat.comNEO Sep 2024 12.500 put (NEO240920P00012500)August 18, 2024 | finance.yahoo.comNEO Sep 2024 12.500 call (NEO240920C00012500)August 18, 2024 | finance.yahoo.comDeltaShares S&P 600 Managed Risk ETF (DMRS)August 12, 2024 | nz.finance.yahoo.comVanguard Group Inc. Buys 41,354 Shares of NeoGenomics, Inc. (NASDAQ:NEO)Vanguard Group Inc. raised its stake in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 0.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,211,019 shares of the medical research company's stock after buying an addiAugust 1, 2024 | marketbeat.comFort Myers-based NeoGenomics reports 2Q results, updates financial outlook for 2024July 31, 2024 | msn.comJanus Henderson Group PLC Decreases Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO)Janus Henderson Group PLC decreased its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 1.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,280,866 shares of the medical researcJuly 31, 2024 | marketbeat.comStrong Buy Recommendation for NeoGenomics Amidst Operational Efficiency and Growth PotentialJuly 31, 2024 | markets.businessinsider.comNeoGenomics, Inc. (NEO) Q2 2024 Earnings Call TranscriptJuly 31, 2024 | seekingalpha.comBuy Rating Affirmed for NeoGenomics Amid Solid Sales Growth and Expanding MarginsJuly 31, 2024 | markets.businessinsider.comBuy Rating Reiterated for NeoGenomics Amidst Strong Financial Performance and Market PositioningJuly 31, 2024 | markets.businessinsider.comNeoGenomics, Inc. (NASDAQ:NEO) Q2 2024 Earnings Call TranscriptJuly 31, 2024 | msn.comNeoGenomics (NASDAQ:NEO) Shares Gap Up to $14.64NeoGenomics (NASDAQ:NEO) Shares Gap Up to $14.64July 30, 2024 | marketbeat.comStephens Reaffirms "Overweight" Rating for NeoGenomics (NASDAQ:NEO)Stephens reiterated an "overweight" rating and set a $19.00 price target on shares of NeoGenomics in a research report on Tuesday.July 30, 2024 | marketbeat.comNeoGenomics (NASDAQ:NEO) Releases Quarterly Earnings ResultsNeoGenomics (NASDAQ:NEO - Get Free Report) released its quarterly earnings data on Monday. The medical research company reported $0.03 EPS for the quarter. The business had revenue of $164.50 million during the quarter, compared to the consensus estimate of $161.82 million. NeoGenomics had a negative return on equity of 3.54% and a negative net margin of 13.79%. The business's revenue for the quarter was up 12.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.09) EPS.July 30, 2024 | marketbeat.comNeoGenomics, Inc. 2024 Q2 - Results - Earnings Call PresentationJuly 29, 2024 | seekingalpha.comNeoGenomics (NASDAQ:NEO) Releases FY 2024 Earnings GuidanceNeoGenomics (NASDAQ:NEO) updated its FY 2024 earnings guidance. The company provided EPS guidance of 0.020-0.070 for the period, compared to the consensus estimate of 0.020. The company also issued revenue guidance of $655.0 millionillion-$667.0 millionillion, compared to the consensus estimate of $655.3 millionillion.July 29, 2024 | marketbeat.comNeoGenomics Reports Second Quarter 2024 ResultsJuly 29, 2024 | finance.yahoo.com946,025 Shares in NeoGenomics, Inc. (NASDAQ:NEO) Purchased by Bellevue Group AGBellevue Group AG purchased a new position in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 946,025 shares of the medical research company's stock, valued at aJuly 28, 2024 | marketbeat.comNeogenomics earnings preview: what Wall Street is expectingJuly 28, 2024 | markets.businessinsider.com Get NeoGenomics News Delivered to You Automatically Sign up to receive the latest news and ratings for NEO and its competitors with MarketBeat's FREE daily newsletter. Email Address 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here NEO Media Mentions By Week NEO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NEO News Sentiment▼-0.650.42▲Average Medical News Sentiment NEO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NEO Articles This Week▼13▲NEO Articles Average Week Get NeoGenomics News Delivered to You Automatically Sign up to receive the latest news and ratings for NEO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MultiPlan News QXO News Etsy News Lyft News Marathon Digital News Nuvei News Clarivate News TriNet Group News Alight News Autohome News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NEO) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeoGenomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeoGenomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
